Palisade Bio

PALI (NasdaqCM)

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing oral phosphodiesterase-4 inhibitor prodrugs for targeted delivery to the terminal ileum and colon in the U.S. Its lead candidate, PALI-2108, is in a Phase 1b trial for inflammatory bowel disease, including ulcerative colitis and fibrostenotic Crohn’s disease. Founded in 2001 and based in Denver, Colorado, it has agreements with Giiant Pharma, the University of California (Newsoara co-development), and Newsoara Biopharma for co-development and distribution.